NO20051339L - Anvendelse av lkB-kinaseinbibitorer ved behandling av smerte. - Google Patents

Anvendelse av lkB-kinaseinbibitorer ved behandling av smerte.

Info

Publication number
NO20051339L
NO20051339L NO20051339A NO20051339A NO20051339L NO 20051339 L NO20051339 L NO 20051339L NO 20051339 A NO20051339 A NO 20051339A NO 20051339 A NO20051339 A NO 20051339A NO 20051339 L NO20051339 L NO 20051339L
Authority
NO
Norway
Prior art keywords
pain
treatment
kinase inhibitors
lkb
lkb kinase
Prior art date
Application number
NO20051339A
Other languages
English (en)
Other versions
NO334309B1 (no
Inventor
Karl Rudolphi
Gerhard Jaehne
Olaf Ritzeler
Martin Michaelis
Gerd Geisslinger
Hans Schaible
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20051339L publication Critical patent/NO20051339L/no
Publication of NO334309B1 publication Critical patent/NO334309B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Paper (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives anvendelse av IkB-kinase-inhibitorer som er egnet for fremstilling av medikamenter for behandling av smerte. Egnede inhibitorer fremstilles fra forbindelsene med formel (I) og (Ia) der substituentene har de angitte betydninger.
NO20051339A 2002-08-17 2005-03-15 Anvendelse av lkB-kinase-inbibitorer ved smerteterapi NO334309B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10237723A DE10237723A1 (de) 2002-08-17 2002-08-17 Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
PCT/EP2003/008628 WO2004022057A1 (de) 2002-08-17 2003-08-05 VERWENDUNG VON IκB-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE

Publications (2)

Publication Number Publication Date
NO20051339L true NO20051339L (no) 2005-05-03
NO334309B1 NO334309B1 (no) 2014-02-03

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051339A NO334309B1 (no) 2002-08-17 2005-03-15 Anvendelse av lkB-kinase-inbibitorer ved smerteterapi

Country Status (34)

Country Link
EP (1) EP1531819B1 (no)
JP (1) JP4504811B2 (no)
KR (2) KR20110135428A (no)
CN (1) CN100398107C (no)
AR (1) AR043045A1 (no)
AT (1) ATE418336T1 (no)
AU (1) AU2003271555B2 (no)
BR (1) BR0313555A (no)
CA (1) CA2495455C (no)
CO (1) CO5690585A2 (no)
CR (1) CR7716A (no)
CY (1) CY1108874T1 (no)
DE (2) DE10237723A1 (no)
DK (1) DK1531819T3 (no)
EC (1) ECSP055609A (no)
ES (1) ES2320118T3 (no)
HK (1) HK1079426A1 (no)
HR (1) HRP20050041B1 (no)
IL (1) IL166780A (no)
MA (1) MA27334A1 (no)
MX (1) MXPA05001218A (no)
MY (1) MY138059A (no)
NO (1) NO334309B1 (no)
OA (1) OA12907A (no)
PL (1) PL212356B1 (no)
PT (1) PT1531819E (no)
RS (1) RS51878B (no)
RU (1) RU2320338C2 (no)
SI (1) SI1531819T1 (no)
TN (1) TNSN05044A1 (no)
TW (1) TWI325782B (no)
UA (1) UA80837C2 (no)
WO (1) WO2004022057A1 (no)
ZA (1) ZA200500323B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7645881B2 (en) 2004-07-22 2010-01-12 Ptc Therapeutics, Inc. Methods for treating hepatitis C
DE102005025225A1 (de) 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201242962A (en) 2010-12-01 2012-11-01 Sumitomo Chemical Co Pyrimidine compound and use for pest control thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2787998B1 (en) * 2011-12-06 2016-11-09 Sanofi Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
AU2015283052B2 (en) * 2014-07-03 2020-01-02 Sanofi 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid ((s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl)-amide for use in the treatment of pain associated to osteoarthritis
KR20210032950A (ko) 2018-07-16 2021-03-25 노파르티스 아게 페닐피페리디닐 인돌 유도체를 제조하기 위한 화학적 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246240T3 (es) * 1999-06-23 2006-02-16 Sanofi-Aventis Deutschland Gmbh Bencimidazoles sustituidos.
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
ES2320118T3 (es) 2009-05-19
DE50310980D1 (de) 2009-02-05
CO5690585A2 (es) 2006-10-31
NO334309B1 (no) 2014-02-03
OA12907A (en) 2006-10-13
HRP20050041B1 (hr) 2013-07-31
KR20050058339A (ko) 2005-06-16
MY138059A (en) 2009-04-30
UA80837C2 (uk) 2007-11-12
CA2495455A1 (en) 2004-03-18
PL212356B1 (pl) 2012-09-28
DE10237723A1 (de) 2004-07-08
HRP20050041A2 (hr) 2006-04-30
EP1531819A1 (de) 2005-05-25
RU2320338C2 (ru) 2008-03-27
CN100398107C (zh) 2008-07-02
CR7716A (es) 2008-11-25
HK1079426A1 (en) 2006-04-07
JP2005539053A (ja) 2005-12-22
TW200417370A (en) 2004-09-16
PT1531819E (pt) 2009-02-18
ZA200500323B (en) 2006-02-22
ATE418336T1 (de) 2009-01-15
AU2003271555A1 (en) 2004-03-29
PL373568A1 (en) 2005-09-05
DK1531819T3 (da) 2009-04-20
IL166780A (en) 2011-11-30
KR101119845B1 (ko) 2012-02-28
JP4504811B2 (ja) 2010-07-14
ECSP055609A (es) 2005-04-18
MXPA05001218A (es) 2005-05-16
AU2003271555B2 (en) 2009-03-26
KR20110135428A (ko) 2011-12-16
WO2004022057A1 (de) 2004-03-18
EP1531819B1 (de) 2008-12-24
TNSN05044A1 (en) 2007-05-14
RS20050070A (en) 2007-06-04
RS51878B (sr) 2012-02-29
CA2495455C (en) 2011-01-11
BR0313555A (pt) 2005-07-12
TWI325782B (en) 2010-06-11
AR043045A1 (es) 2005-07-13
MA27334A1 (fr) 2005-05-02
SI1531819T1 (sl) 2009-06-30
CN1674899A (zh) 2005-09-28
RU2005107419A (ru) 2005-08-10
IL166780A0 (en) 2006-01-15
CY1108874T1 (el) 2014-07-02

Similar Documents

Publication Publication Date Title
NO20051339L (no) Anvendelse av lkB-kinaseinbibitorer ved behandling av smerte.
NO20050828L (no) lndol-3-svovelderivater
EA200700099A1 (ru) Производные пиридина
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
GB0112348D0 (en) Compounds
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
UA84175C2 (ru) Гетероциклические ингибиторы мэк и их применение
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
NO20082496L (no) Pyrazinderivater
NO20061839L (no) Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav
NO20073926L (no) Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
MY144655A (en) Pyrimidine urea derivatives as kinase inhibitors
NO20090580L (no) Syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
DE60320012D1 (de) Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen
NO20062583L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
DE602004022668D1 (de) 5-gliedrige heterocyclische p-38 inhibitoren
NO20051008L (no) Nye imidazolforbindelser som transformerende vekst faktor (TGF) inhibitorer
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
ATE520668T1 (de) Sigmarezeptor-inhibitoren
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees